SK Bioscience obtained item approval on June 29 and supplied vaccines on September under a pre-purchase contract with the government, but suspended production due to low market demand.
Seoul [South Korea], February 22 (ANI/Global Economic): As 'flurona,' which means having both COVID-19 and influenza at the same time, is recently popping up in many countries, including Israel, Brazil, the U.S., Hungary, and Croatia, concerns on 'twindemic' have emerged.
Seoul [South Korea], February 9 (ANI/Global Economic): As the Omicron COVID-19 variant, which is now the most dominant strain in the world, rapidly spread in Korea, SK Bioscience also started developing Omicron-specific vaccines.
Seoul [South Korea], January 3 (ANI/Global Economic): SK Bioscience signed a contract to pre-purchase up to 5 million doses of Novavax's COVID-19 vaccine 'NVX-CoV2373' in 2022.
Seoul [South Korea], December 29 (ANI/Global Economic): As SK Bioscience announced its plan to open a new R&PD center in Songdo, Incheon, three Korean bio companies called 'Big 3,' including Celltrion, Samsung Biologics, and SK Bioscience, are expected to gather in Songdo Bio-cluster.
Seoul [South Korea], May 11 (ANI/Global Economic): This year, Mirae Asset Securities showed the largest number of complaints among securities companies.